NewAmsterdam Pharma (NAMS) Earnings Date & Reports

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

NAMS is expected to report earnings to fall 46.56% to -49 cents per share on May 07

NewAmsterdam Pharma NAMS Stock Earnings Reports

Q1'25

Est.

$-0.50

Q4'24

Beat

by $0.03

Q3'24

Beat

by $0.32

Q2'24

Beat

by $0.17

Q1'24

Missed

by $0.44

The last earnings report on February 26 showed earnings per share of -93 cents, beating the estimate of -95 cents. With 345.32K shares outstanding, the current market capitalization sits at 1.92B.

View a ticker or compare two or three

Compare

NAMS